Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aduro gets $200m as Novartis steps up immuno-oncology

This article was originally published in Scrip

Executive Summary

Aduro Biotech has secured a $200m upfront payment from Novartis as the latter steps up its activity in immunotherapy for cancer. The deal brings Novartis an early-stage immuno-oncology platform targeting the Stimulator of Interferon Genes (STING) pathway, adding to its ongoing programs using chimeric antigen receptor T-cell (CART) technology and checkpoint inhibitors.


Related Content

Finance Watch: Bitcoin For Biopharma? Agenus Gives BEST A Shot
An Inflammatory Deal: Bristol Commits Up To $2.3bn To Buy IFM Therapeutics
Immuno-Oncology Data Drive Deal Dollars Higher
INTERVIEW: Novartis' Oncology Chief On Sharpening Its Competitive Advantage


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts